Abstract library

166 results for "health professional".
#2179 Exploring Nutrition Screening and Management Practices amongst Health Professionals Managing Patients with Neuroendocrine Tumors
Introduction: Patient’s with neuroendocrine tumours (NET) are at nutritional risk due to symptoms and side-effects of treatment. Current evidence based guidelines lack information regarding optimal nutritional management and supportive care.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Erin Kennedy
Authors: Kennedy E, Kiss N, Michael M, Gough K, ...
#2701 Assessing the Gaps in Experience and Knowledge of Australian Primary Health Care Professionals (GPs), in Treating and Caring for the Increasing Number of Australian Neuroendocrine Tumour (NET) Patients
Introduction: Conservatively,the incidence of NETs is 7 / 000' p.a, however,the prevalence of patients living with NETs is higher,40/000',making it the 2nd most common GI malignancy after colorectal cancer.Patients are living longer,however,with impaired quality of life.Management of debilitating symptoms such as diarrhoea,fatigue,anxiety,and flushing are complex and heterogenous.
Conference: 17th Annual ENETS Conference (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Simone Leyden
Authors: Leyden S, Cummins M, Wakelin K, ...
#209 A Randomized, Cross-Over Study in Patients with Neuroendocrine Tumors (NETs) to Assess Patient Preference of Lanreotide Autogel Given by Either Self/Partner or Healthcare Professional
Introduction: Ready-to-use Lanreotide Autogel provides the option of self/partner administration for patients with NET. This is anticipated to reduce treatment cost and negative impact on daily life.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MSc Anders Öhberg
#539 Patterns of Care of Neuroendocrine Cancer in Ontario: Health Services Delivery
Introduction: Delayed diagnosis and treatment of NETs may result in increased health care utilization, medical costs and patient distress. Patients may be treated by different specialists and modalities.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Simron Singh
Authors: Singh S, Cukier M, Liu N, Saskin R, ...
#1291 How Long Is the Piece of String? – How Patients Negotiate the Uncertainties of a NET Diagnosis
Introduction: NET Patient Interviews
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: Dr David Wyld
Authors: Wyld D, Plage S, Burge M, Broom A, ...
Keywords: Interviews
#1326 Clinical Nurse Specialist in NET Patients at Institut Català d’ Oncologia - ICO
Introduction: A Functional Unit model brings together multidisciplinary professionals participating in a committee. Its aim is to optimize diagnostic and therapeutic intervals, get consensus on the best-individual treatment option & best evidence. Our unit-NET, was establish 10 years ago & last 4 got a clinical nurse specialist-CNS
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: RN, PhDcandidate Paz Fernandez
Keywords: Clinical nurse
#2955 Development of an EORTC Quality of Life Questionnaire for Patients with Pancreatic Neuroendocrine Tumours: Phases 1-3
Introduction: Measuring quality of life (QoL) in Pancreatic Neuroendocrine Tumours (pNET) involves assessing issues from symptoms, disease and treatment. The validated gastrointestinal NETs module (EORTC QLQ-GINET21) is used with EORTC QLQ-C30 but there are concerns it inadequately measures QoL in pNET.
Conference: 17th Annual ENETS Conference (2020)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Elizabeth Friend
#44 Somatostatin analogue therapy and RAND-36 health-related quality of life scores in patients with neuroendocrine tumors
Introduction: Somatostatin analogues (SSAs) are used in patients with neuroendocrine tumors (NETs) for the management of carcinoid syndrome and/or delay of disease progression.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jennifer L Beaumont
Authors: Yao J C, Beaumont J L, Choi S, Cella D, ...
#2956 Somatostatin Analogs: The Economic Value of Lanreotide Autogel Delivery Attributes in the Treatment of GEP-NET versus Octreotide LAR – A UK Budget Impact Analysis
Introduction: Lanreotide autogel (LAN) and octreotide long acting release (OCT) are long-acting somatostatin analogues (LA-SSAs) used to treat patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, the treatments differ in terms of injection route, need for administration by a health care professional and dosing interval.
Conference: 17th Annual ENETS Conference (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Marion Feuilly
#481 Quality of Life in Patients with Neuroendocrine Tumors: A Cross-Sectional Study
Introduction: Living with cancer affects not only physical and mental health but also the social and professional life of the patient. Measuring quality of life (Qol) is one way to learn from the patient perspective.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MRS Lise Plum
Authors: Plum L, Knigge U, ...
Keywords: quality of life
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss out any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team